Literature DB >> 23449477

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.

H M Aliabadi1, P Mahdipoor, H Uludağ.   

Abstract

Enhanced survival mechanisms of malignant cells in combination with elevated levels of drug transporters can sustain an undesirable resistance against drug therapy. Short interfering RNA (siRNA) delivery against targets involved in aberrant mechanisms is a promising approach and we hypothesize that simultaneous silencing of multiple targets could prove more advantageous than common approach to silence individual targets. To explore this approach, we targeted anti-apoptotic proteins myeloid cell leukemia 1 (Mcl-1) and survivin along with the efflux pump P-glycoprotein (P-gp) in drug-resistant breast cancer cells. Polymeric siRNA delivery was employed for this purpose by using small polyethylenimine (PEI) substituted with lipids. While silencing Mcl-1 caused ∼90% cell death in wild-type cells, this effect was less significant in P-gp over-expressing cells. An additive effect for Mcl-1 and P-gp silencing was evident in the latter cells, where simultaneous silencing of these targets created a significantly higher effect compared with silencing each individual target. Prolonged exposure of wild-type cells to doxorubicin (DOX) resulted in upregulation of P-gp, breast cancer resistance protein, survivin and Mcl-1. Dual silencing of P-gp and Mcl-1 again resulted in an additive effect in resistance-induced cells, which displayed an increased dependency on Mcl-1 for survival. Cytotoxic effect of DOX was also enhanced in resistance-induced cells after silencing Mcl-1. We conclude that polymer-mediated siRNA delivery can silence multiple targets simultaneously and reverse drug resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449477     DOI: 10.1038/cgt.2013.8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  8 in total

1.  Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.

Authors:  Gayong Shim; Sangbin Lee; Junhyeok Choi; Soondong Lee; Chan-Wha Kim; Yu-Kyoung Oh
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

2.  Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.

Authors:  Subrata K Ghosh; Mehmet V Yigit; Masashi Uchida; Alana W Ross; Natalie Barteneva; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

3.  Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.

Authors:  Kenichiro Doi; Qiang Liu; Krishne Gowda; Brian M Barth; David Claxton; Shantu Amin; Thomas P Loughran; Hong-Gang Wang
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

4.  Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Authors:  Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharsky; Nicole Chan; Hasan Uludağ
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

5.  Expression of P-gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance.

Authors:  Feng Gao; Wanwei Dong; Wei Yang; Jia Liu; Zhihong Zheng; Kailai Sun
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

6.  Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models.

Authors:  Peican Zhu; Hamidreza Montazeri Aliabadi; Hasan Uludağ; Jie Han
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

7.  Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer.

Authors:  Ting Zhou; Lin Zhang; Tingting Liu; Yunpeng Yang; Fan Luo; Zhonghan Zhang; Yan Huang; Hongyun Zhao; Li Zhang; Yuanyuan Zhao
Journal:  Ann Transl Med       Date:  2020-12

8.  Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.

Authors:  Manoj B Parmar; Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharski; Robert Maranchuk; Judith C Hugh; Hasan Uludağ
Journal:  Front Bioeng Biotechnol       Date:  2015-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.